Your Clear Path to First-in-Human Approval and Beyond
Getting to first-in-human trials is the most critical and most scrutinized milestone in drug development. Our IND-enabling team combines 40+ years of GLP execution with regulatory scientists who have sat on both sides of the FDA advisory table, ensuring your program passes from day one.
1,500+
IND programs conducted annually
8,500+
GLP studies executed each year
> 80%
of novel FDA-approved drugs in the past four years supported by our services
- ✓ End-to-end IND-enabling program design, sequencing, and execution
- ✓ GLP and non-GLP studies with documentation aligned for submission
- ✓ Real-time milestone tracking and visibility through Apollo™
- ✓ Integrated bioanalytical and safety pharmacology support
IND Enabling Services Brochure
Conquer IND hurdles with our comprehensive solutions. We work with you in lockstep and provide tailored solutions you need to expedite your drug development timeline.
Explore now
Dispelling the “Cookie Cutter” Fallacy of Small Molecule IND
View this webinar to discover how to adapt your approach to your IND program’s unique challenges to gain a competitive edge.
Watch the webinar
IND Success Through Nonclinical Strategy
See how integrated nonclinical and regulatory support helped Invizius secure MHRA approval to advance H-Guard® into first in human trials.
Read the case study
Our experts are available to help provide guidance throughout your program. Please provide us with more information about your requirements and we will contact you to discuss how we can support your journey to market.
- Need regulatory advice? Our scientific advisory experts can help you outline your IND-enabling studies to meet your milestones and achieve the relevant data necessary to move into first-in-human clinical trials.
- Have a question? We have answers and can offer solutions to your greatest challenges.
- Want more information? We’re happy to explain our services, methods, and technologies in greater detail.
- Is your project ready to go? Request a quote.
I have confidence in designing my pre-clinical packages with Charles River’s guidance. When you trust a contractor, making management decisions about timelines and costs, as well as getting Board agreement, is a lot easier.”
Dr. Magnus Nicolson, COO, Invizius H-Guard® MHRA First-in-Human Approval


